HLS Therapeutics obtains public reimbursement for Vascepa in Quebec

24 May 2022 - Quebec becomes the first province to reimburse Vascepa for the reduction of cardiovascular risk in patients with ...

Read more →

Boehringer Ingelheim Canada announces reimbursement for Ofev (nintedanib) in seven public drug plans for the treatment of progressive fibrosing interstitial lung diseases

3 May 2022 - Boehringer Ingelheim is pleased to announce that Ofev (nintedanib), is now available for public reimbursement in Quebec, ...

Read more →

Astellas announces reimbursement for Xospata (gilteritinib) in most provinces for patients with relapsed or refractory acute myeloid leukaemia with a FLT3 mutation

21 April 2022 - Having access to an additional treatment option offers hope for Canadian adult AML patients with relapsed ...

Read more →

Teva Canada welcomes public drug plan reimbursement by Alberta, Saskatchewan, Québec, Veteran Affairs Canada and the non-insured health benefits program for patients prescribed Ajovy (fremanezumab) for the preventive treatment of migraine in adults

2 March 2022 - Public formulary and program coverage makes AJOVY® accessible to more migraine patients across Canada. ...

Read more →

AbbVie announces first provincial reimbursements for Venclexta (venetoclax) in combination with azacitidine for acute myeloid leukaemia patients

10 February 2022 - Following the signing of an agreement between AbbVie and the pan-Canadian Pharmaceutical Alliance, Quebec, Saskatchewan, and ...

Read more →

Quebec to impose health tax on unvaccinated Canadians

12 January 2022 - The Canadian province of Quebec will charge a health tax to residents who are not vaccinated ...

Read more →

Valeo Pharma obtains public reimbursement for Enerzair Breezhaler and Atectura Breezhaler in Quebec and Nova Scotia

15 December 2021 - Public reimbursement now includes Alberta, Quebec and Nova Scotia, representing approximately 37% of the Canadian population. ...

Read more →

Novartis applauds Quebec, the first province to list Zolgensma for the treatment of paediatric patients with spinal muscular atrophy

15 October 2021 - Public reimbursement under the Régie de l'assurance maladie du Québec, effective October 20th will apply for children ...

Read more →

Quebec extends public reimbursement of Dupixent (dupilumab) for the treatment of moderate to severe atopic dermatitis to include adolescents

1 June 2021 - Public reimbursement under the Régie de l'assurance maladie du Québec will now apply for Canadians aged ...

Read more →

Quebec announces intention to implement a biosimilar switching policy

18 May 2021 - Biosimilars Canada today congratulated the Government of Quebec and Minister of Health and Social Services Christian ...

Read more →

Sandoz Canada congratulates the Quebec government on implementing a shift towards biosimilars

18 May 2021 - The shift announced by Quebec will follow a similar approach to policies introduced in British Columbia, Alberta ...

Read more →

Ontario and Quebec provide reimbursement for HIV therapies Pifeltro (doravirine) and Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate)

18 November 2019 - For more than 30 years, Merck has been committed to scientific research and discovery in HIV that ...

Read more →

Patients in Quebec now have access to Dupixent for the treatment of moderate-to-severe atopic dermatitis

22 October 2019 - Quebec becomes the first province to list Dupixent for public reimbursement in adult patients. ...

Read more →

Novartis completes certification of initial sites in Quebec for first approved Canadian CAR-T therapy, Kymriah (tisagenlecleucel)

9 October 2019 - Quebec government to reimburse Kymriah therapy for certain patients with life-threatening cancers who are in critical ...

Read more →

Addition of Kisqali to drug plan in Quebec expands access to treatment for metastatic breast cancer

19 September 2019 - Provincial reimbursement provides public access to treatment that may delay the progression of advanced breast cancer. ...

Read more →